Payment & Shipping Terms | Supply Capacity |
Payment Terms: | T/T, WU | Production Capacity: | 500Ton/year |
Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Trypsin inhibitor, pancreatic basic (CAS: 9087-70-1;9004-04-0)
Item | Index |
Molecular Formula | C284H432N84O79S7 |
Molecular weight | 6511.44 |
Specification | CP/USP/EP |
Appearance | White to light yellow lyophilized powder |
Storage Condition | 2-8°C |
The drug aprotinin (Trasylol, previously Bayer and now Nordic Group pharmaceuticals), is the small protein bovine pancreatic trypsin inhibitor, or BPTI, which inhibits trypsin and related proteolytic enzymes. Under the trade name Trasylol, aprotinin was used as a medicationadministered by injection to reduce bleeding during complex surgery, such as heart and liver surgery. Its main effect is the slowing down offibrinolysis, the process that leads to the breakdown of blood clots. The aim in its use was to decrease the need for blood transfusions during surgery, as well as end-organ damage due to hypotension (low blood pressure) as a result of marked blood loss. The drug was temporarily withdrawn worldwide in 2007 after studies suggested that its use increased the risk of complications or death; this was confirmed by follow-up studies. Trasylol sales were suspended in May 2008, except for very restricted research use. In February 2012 the European Medicines Agency (EMA) scientific committee reverted its previous standpoint regarding aprotinin, and has recommended that the suspension be lifted. Nordic became distributor of aprotinin in 2012.
Chemistry
Pancreatic trypsin inhibitorIdentifiersOrganismSymbolEntrezPDBRefSeq (mRNA)RefSeq (Prot)UniProtOther dataChromosome
